RxDoctor Payments Data

Madhu Gupta, MD

Family Medicine · Walnut Creek, CANPI 1265628473

Payments from drug & device makers

$3,242in general payments, 2019–2025

Across 140 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$709
  • AstraZeneca$531
  • Bayer$334
  • Novo Nordisk$324
  • Pfizer$319
  • Lilly USA, LLC$164
  • plus $861 from 20 others

What the payments were for

  • Food & beverage$3,22599%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,242 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$88,664
Medicare patients
199
Services billed
1,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$16,913
Breo ElliptaFluticasone/Vilanterol12$5,107
Atorvastatin Calcium192$2,354
Levothyroxine Sodium130$1,882
Eszopiclone18$1,631
Rosuvastatin Calcium40$1,092
SynthroidLevothyroxine Sodium16$996
Losartan Potassium72$957
Albuterol Sulfate HfaAlbuterol Sulfate16$926
Escitalopram Oxalate32$758
Metformin Hcl76$731
Metoprolol Succinate37$698
Gabapentin34$670
Fluticasone Propionate27$588
Lisinopril81$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18$16,91311 claims
GSKBreo Ellipta$152$5,10712 claims
AbbVieSynthroid$60$99616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →